17Dec/12

CTI announces preclinical study of Pixuvri, provides mechanism for lower … – pharmabiz.com

CTI announces preclinical study of Pixuvri, provides mechanism for lower
pharmabiz.com
The EMA Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one to three prior

and more »

17Dec/12

Preclinical Study Provides Potential Mechanisms for Lower Cardiotoxicity in … – PharmaLive (press release) (subscription)

Preclinical Study Provides Potential Mechanisms for Lower Cardiotoxicity in
PharmaLive (press release) (subscription)
The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who

and more »